Report shows U.S. biotechs are wary of Chinese partnerships due to looming BIOSECURE Act

A looming anti-China biotechnology bill has spooked U.S. life sciences companies, according to a new report.

The report by the London- and Boston-based L.E.K. Consulting quantifies what until now has been mostly a vibe check. At this year’s Biotechnology Innovation Organization’s international conference, multiple biotech companies told STAT they plan to switch from striking deals with Chinese companies to U.S.-based drug manufacturers, even though doing so will be more costly, and the BIOSECURE Act is still just a proposal, albeit one with traction in Congress.

“The Act, regardless of passage, is likely to reshape how the global biopharma industry operates,” according to the report, which was written by an analyst in China.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In